Formulation Development
George Medicines Files NDA for Novel Low Dose Triple Combination for Treatment of Hypertension Following Successful Phase 3 Development Program
George Medicines recently announced its submission to the US FDA of a New Drug Application (NDA) for GMRx2, George Medicines’ lead pipeline candidate for the…
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Annovis Bio Inc. recently announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1)…
Compass Therapeutics Completes Patient Enrollment in Randomized Study of CTX-009 in Combination With Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics, Inc. recently announced it completed enrollment of the planned 150 patients in COMPANION-002, its randomized Phase 2/3 clinical trial of CTX-009 in patients…
New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Clearmind Medicine Inc. recently announced a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating…
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
NeOnc Technologies Holdings, Inc. has begun patient enrollment for the Phase 2 clinical trial of NEO100-02, the company’s first of two drug candidates proceeding through…
Salubris Biotherapeutics Announces Approval to Initiate Phase 1 Clinical Trial of a 5T4-Targeted ADC in Solid Tumors
Salubris Biotherapeutics, Inc. recently announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06 in…
FDA Review of PsiGAD2 IND Complete; Clinical Trial for Psilocybin-Assisted Psychotherapy in Patients With Generalized Anxiety Disorder to Proceed
Incannex Healthcare Inc. recently announced it has received approval from the US FDA to conduct its Investigational New Drug (IND) opening Phase 2 clinical trial.…
MBX Biosciences Raises $63.5 Million to Advance Precision Endocrine Peptide Platform
MBX Biosciences, Inc. recently announced a $63.5-million Series C financing led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds…
Cresset Collaborates With Enamine to Enable the Design of Exciting New Targeted Protein Degraders
Cresset recently announced an extension of the global collaboration with Enamine, the world’s leading chemical and biological contract research organization and producer of novel building…
Shapiro Administration Invests Nearly $3 Million to Bring Adare Pharma Solutions’ Headquarters to Pennsylvania
Governor Josh Shapiro recently announced the Commonwealth is investing nearly $3 million in Adare Pharma Solutions to support the life sciences company’s growth and headquarters relocation…
FDA Accepted BLA for the First & Only Ticagrelor Reversal Agent for Filing & Priority Review
SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and…
DiamiR Biosciences Secures Patent Covering the Use of microRNA Biomarkers From Bodily Fluids for Differential Diagnosis of ALS
DiamiR recently announced its European Patent Application No. 17 771018.3 titled Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases was…
Bayer Submits NDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
Bayer recently announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the US FDA for the treatment of…
FDA Approves Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Limited recently announced the US FDA approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia…
AC Immune Unveils Novel Therapeutic ADC Technology for Improved Efficacy in Neurodegenerative Diseases
AC Immune SA recently unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer Antibody Drug Conjugate) in an oral presentation at the annual…
GeoVax Announces Phase 2 Plans for Cancer Therapy Following Clinical Advisory Committee Review
GeoVax Labs, Inc. recently announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical advisory committee review. GeoVax and…
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease
Vaccinex, Inc. recently announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. Topline results were presented by Eric Siemers,…
GSK Leverages Genedata Biologics as End-to-End Automation & Data Science Platform
Genedata recently announced GSK, a leading biopharma company, has extended the use of Genedata Biologics to new application areas in data sciences, analytics, and R&D automation.…
Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
Ocular Therapeutix, Inc. recently announced the first patients have been enrolled in the Phase 3 SOL-R clinical trial evaluating repeat dosing of AXPAXLI (axitinib intravitreal…
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX2-73 in Fragile X Syndrome (Major Cause of Autism)
Anavex Life Sciences Corp. recently reported positive preclinical results in directly to humans’ translatable biomarkers for individuals with FXS for ANAVEX2-73 (blarcamesine), in a disease…
